Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Coronavirus Update: Lilly To Seek EUA For Olumiant

Plus: Gilead Agrees European Procurement Deal On Veklury

Oct 09 2020

• By Scrip Team

Indianapolis - Circa April 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals IV — Lilly has reported encouraging data from Olumiant's combination with Gilead's Veklury

Related Content

J&J’s COVID Vaccine Contract With US Bucks Trend Of Increasingly Lucrative Deals

Aug 06 2020

Coronavirus Update: Trump Tests Positive, US Pause Remains On AstraZeneca Vaccine

Oct 02 2020

Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data

Oct 07 2020

J&J Taps Biological E For Up To 500m Coronavirus Vaccine Doses A Year

Aug 14 2020

After Blood Plasma Emergency Use Authorization, Can Takeda Develop A More Potent Alternative?

Aug 24 2020

Coronavirus Update: Gilead To Meet Global Remdesivir Demand By October

Aug 07 2020

Early Data Support J&J’s COVID-19 Vaccine Push Into Phase III

Sep 28 2020

Coronavirus Update: J&J’s Single Shot Could Catch Up With Frontrunners

Sep 24 2020

Lilly’s Olumiant Cuts COVID-19 Hospital Stays By One Day

Sep 14 2020

Second Cellectis CAR-T Therapy On Clinical Hold, Dosing Could Be Issue

Jul 08 2020

NIH Pushes Ahead With First COVID-19 Combo: Remdesivir Plus Lilly’s Olumiant

May 12 2020

Related Companies

Johnson & Johnson

Pfizer Inc.

Moderna, Inc.

Biological E Limited.

Gilead Sciences, Inc.

Eli Lilly and Company

AbCellera Biologics Inc.

Shanghai Junshi Biosciences Co., Ltd.

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Companies Commercial Coronavirus COVID-19 BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window